NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia flag Australia · Delayed Price · Currency is AUD
0.0960
-0.0040 (-4.00%)
Mar 4, 2026, 3:14 PM AEST

ASX:NSB Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Income
-3.18-1.850.32-1.07-10.44-3.18
Depreciation & Amortization
0.670.090.090.060.060.06
Stock-Based Compensation
0.80.80.130.241.350.63
Other Operating Activities
0.31-----
Change in Accounts Receivable
-0.04-0.04-0.010.08-0.07-0.03
Change in Accounts Payable
0.050.05-0.5-1.581.990.11
Change in Other Net Operating Assets
000.01-0.030.16-0.19
Operating Cash Flow
-1.39-0.940.04-2.3-6.94-2.6
Capital Expenditures
---0--0-0.03
Cash Acquisitions
-0.04-0.04----
Investing Cash Flow
-5.29-0.04-0--0-0.03
Issuance of Common Stock
3.53.5---13.32
Other Financing Activities
-0.21-0.21---0.18
Financing Cash Flow
3.293.29---13.51
Net Cash Flow
-3.392.310.04-2.3-6.9510.88
Free Cash Flow
-1.39-0.940.04-2.3-6.95-2.63
Free Cash Flow Margin
-436.90%-1.92%-46.52%--274.46%
Free Cash Flow Per Share
-0.01-0.01--0.02-0.05-0.02
Levered Free Cash Flow
-0.31-0.34-0.19-1.97-3.08-1.49
Unlevered Free Cash Flow
-0.3-0.34-0.18-1.97-3.08-1.49
Change in Working Capital
0.010.01-0.5-1.542.08-0.11
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.